GNA15 |
P30679
|
G protein subunit alpha 15
|
Enzyme modulator
|
6.0E-03 |
0.780 |
0.269 |
ZNF384 |
Q8TF68
|
zinc finger protein 384
|
|
1.00 |
0.705 |
0.269 |
ALL1 |
|
Leukemia, acute lymphocytic, susceptibility to, 1
|
|
|
0.636 |
0.269 |
CEBPE |
Q15744
|
CCAAT enhancer binding protein epsilon
|
Transcription factor
|
7.1E-03 |
0.674 |
0.385 |
BAALC |
Q8WXS3
|
BAALC binder of MAP3K1 and KLF4
|
|
4.4E-03 |
0.631 |
0.385 |
P2RY8 |
Q86VZ1
|
P2Y receptor family member 8
|
G-protein coupled receptor
|
3.4E-03 |
0.700 |
0.385 |
EVPL |
Q92817
|
envoplakin
|
Cellular structure
|
5.7E-25 |
0.599 |
0.423 |
FPGS |
Q05932
|
folylpolyglutamate synthase
|
Enzyme
|
1.2E-06 |
0.644 |
0.423 |
HOXB4 |
P17483
|
homeobox B4
|
|
6.0E-02 |
0.647 |
0.423 |
AFF1 |
P51825
|
AF4/FMR2 family member 1
|
Transcription factor
|
0.71 |
0.659 |
0.423 |
PTP4A2 |
Q12974
|
protein tyrosine phosphatase 4A2
|
|
0.97 |
0.695 |
0.423 |
IRX3 |
P78415
|
iroquois homeobox 3
|
Transcription factor
|
0.89 |
0.705 |
0.462 |
MEF2D |
Q14814
|
myocyte enhancer factor 2D
|
Transcription factor
|
1.00 |
0.608 |
0.500 |
MOS |
P00540
|
MOS proto-oncogene, serine/threonine kinase
|
Kinase
|
0.59 |
0.617 |
0.500 |
ARID5B |
Q14865
|
AT-rich interaction domain 5B
|
Transcription factor
|
1.00 |
0.638 |
0.500 |
PIM2 |
Q9P1W9
|
Pim-2 proto-oncogene, serine/threonine kinase
|
Kinase
|
0.95 |
0.606 |
0.538 |
FZR1 |
Q9UM11
|
fizzy and cell division cycle 20 related 1
|
Enzyme modulator
|
1.00 |
0.670 |
0.538 |
CNTNAP1 |
P78357
|
contactin associated protein 1
|
|
3.4E-05 |
0.554 |
0.577 |
PRAME |
P78395
|
preferentially expressed antigen in melanoma
|
|
2.4E-07 |
0.531 |
0.577 |
CASC15 |
|
cancer susceptibility 15
|
|
|
0.603 |
0.577 |
CD22 |
P20273
|
CD22 molecule
|
|
0.80 |
0.556 |
0.615 |
PCM1 |
Q15154
|
pericentriolar material 1
|
|
3.7E-16 |
0.644 |
0.615 |
EBF1 |
Q9UH73
|
EBF transcription factor 1
|
|
1.00 |
0.584 |
0.654 |
FLT3 |
P36888
|
fms related receptor tyrosine kinase 3
|
Kinase
|
0.61 |
0.462 |
0.654 |
HOXA@ |
|
homeobox A cluster
|
|
|
0.599 |
0.654 |